Cargando…

GIFT4-augmented B cells for melanoma immunotherapy

Detalles Bibliográficos
Autores principales:	Deng, Jiusheng, Pennati, Andrea, Yuan, Shala, Kudchadkar, Ragini, Lawson, David, Galipeau, Jacques
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288769/ http://dx.doi.org/10.1186/2051-1426-2-S3-P9

Ejemplares similares

GIFT4 fusokine converts leukemic B cells into immune helper cells
por: Deng, Jiusheng, et al.
Publicado: (2016)

Maltose-Binding Protein Fusion Allows for High Level Bacterial Expression and Purification of Bioactive Mammalian Cytokine Derivatives
por: Pennati, Andrea, et al.
Publicado: (2014)

Complications of sequential immunotherapy in metastatic melanoma
por: Bufalino, Shams, et al.
Publicado: (2015)

Cutaneous and Noncutaneous Adverse Effects in Patients with Advanced Melanoma Receiving Immunotherapy
por: Yeung, Howa, et al.
Publicado: (2023)

Blood B Cell and Regulatory Subset Content in Multiple Sclerosis Patients
por: Habib, Jakob, et al.
Publicado: (2015)

Harnessing the potential of radiation treatment of brain metastases to improve melanoma immunotherapy
por: McNeilly, Corey D, et al.
Publicado: (2015)

Immune infiltrates impact on the prediction of prognosis and response to immunotherapy of melanoma patients
por: Vasaturo, Angela, et al.
Publicado: (2015)

Melanoma-derived Wnt5a conditions dendritic cells to promote regulatory T cell differentiation via the upregulation of indoleamine 2,3-dioxygenase: novel pharmacological strategies for augmenting immunotherapy efficacy
por: Zhao, Fei, et al.
Publicado: (2014)

Immunocytokine augments local and abscopal response and animal survival when added to radiation and CTLA-4 checkpoint inhibition in a murine melanoma model
por: Morris, Zachary S, et al.
Publicado: (2015)

Purine nucleoside phosphorylase inhibitors - an immunotherapy with novel mechanism of action for the treatment of melanoma
por: Bantia, Shanta
Publicado: (2015)

Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5- fluorouracil chemotherapy in the B16 melanoma model
por: Rakhmilevich, Alexander, et al.
Publicado: (2013)

Antigen-specific TIL therapy for melanoma: a flexible platform for personalized cancer immunotherapy
por: Kelderman, Sander, et al.
Publicado: (2013)

Interaction between effector and memory cd8+ t cells enhances melanoma adoptive immunotherapy
por: Contreras, Amanda, et al.
Publicado: (2015)

A Fusion Cytokine Coupling GMCSF to IL9 Induces Heterologous Receptor Clustering and STAT1 Hyperactivation through JAK2 Promiscuity
por: Li, Pingxin, et al.
Publicado: (2013)

Intra-patient intra-tumoral immune heterogeneity is evident at progression on targeted therapy and immunotherapy for melanoma
por: Reuben, Alexandre, et al.
Publicado: (2014)

An image analysis algorithm based on the hue saturation density transformation, an important tool for melanoma immunotherapy research
por: Dzubay, Jeffrey A, et al.
Publicado: (2014)

Gifts and Gifts
por: Pratt, Ben. H.
Publicado: (1873)

Tissue factor-targeted immunotherapy of melanoma and triple negative breast cancer using a second generation ICON
por: Hu, Zhiwei, et al.
Publicado: (2015)

High Th17:Treg ratio may predict complete response to HDIL-2 in the setting of melanoma
por: Diller, Maggie L, et al.
Publicado: (2015)

Multimeric forms of 4-1BBL as stimulators of T cells for adoptive immunotherapy
por: Kornbluth, Richard S, et al.
Publicado: (2014)

A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
por: Brohl, Andrew S., et al.
Publicado: (2016)

Interleukin-4 receptor targeted immunotherapy of human bladder cancer in animal models
por: Joshi, Bharat H, et al.
Publicado: (2014)

B16F0 melanoma exosomes deliver a unique and complex biological payload that includes Ptpn11 to suppress T lymphocyte function
por: Wu, Yueting, et al.
Publicado: (2015)

ErbB2/HER2-specific NK cells for adoptive cancer immunotherapy
por: Zhang, Congcong, et al.
Publicado: (2013)

ErbB2/Her2-specific NK cells for adoptive immunotherapy of glioblastoma
por: Zhang, Congcong, et al.
Publicado: (2014)

Development of a personalized cellular ex-vivo cbl-b silencing cancer immunotherapy
por: Lametschwandtner, Guenther, et al.
Publicado: (2014)

B7-h3-specific engager T cells for the immunotherapy of pediatric solid tumors
por: DeRenzo, Christopher, et al.
Publicado: (2015)

A "prime-pull" immunotherapy approach using a lentiviral vector and intratumoral TLR4 agonist redirects cytotoxic T cells
por: Albershardt, Tina C, et al.
Publicado: (2014)

Preparative immunotherapy with anti-OX40 and anti-CTLA4 improves the response to chemotherapy
por: Friedman, David J, et al.
Publicado: (2014)

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
por: Caputo, Emilia, et al.
Publicado: (2015)

Strengthening training and supervisory systems to improve Skilled Birth Assistance in Jharkhand, India
por: Pasricha, Ragini, et al.
Publicado: (2012)

Augmented renal clearance in traumatic brain injury
por: Udy, A, et al.
Publicado: (2010)

An aid to the viewing and reporting of the mammograms of the augmented breast
por: Miller, HJ, et al.
Publicado: (2006)

Clinical value of Melanoma Inhibitory Activity in stratifying malignant melanoma patients
por: Sandru, Angela, et al.
Publicado: (2015)

Exome sequencing in primary melanoma identifies novel drivers of melanoma progression
por: Montagnani, Valentina, et al.
Publicado: (2015)

A MCP1 fusokine with CCR2-specific tumoricidal activity
por: Rafei, Moutih, et al.
Publicado: (2011)

Immunologic hierarchy and promiscuity of melanoma helper peptides
por: Hu, Yinin, et al.
Publicado: (2013)

Stereotactic body radiation therapy and CTLA-4 blockade as a novel therapy for advanced melanoma
por: Twyman, Christina, et al.
Publicado: (2013)

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival
por: Broucek, Joseph R, et al.
Publicado: (2013)

Melanoma Inhibitory Activity and regional lymph node status in malignant melanoma patients
por: Sandru, Angela, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_eevug4jnjelrr5jbhsivmgi2ns